The development of modern approaches to the pharmacotherapy of rheumatoid arthritis (RA) in combination with arterial hypertension (AH), abdominal obesity (AB), and type 2 diabetes mellitus (T2DM) remains relevant today. In particular, due to inadequate control of systemic inflammation, simultaneous administration of a large number of potentially dangerous drugs: nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and glucocorticosteroids (GCs), a comorbid pathology occurs that complicates the course and treatment of RA. In order to solve this problem, it is necessary to correct the risk factors of RA, choose an adequate diseasemodifying antirheumatic therapy (DMRT) and treat concomitant pathology. This will improve the prognosis and improve the quality of life of RA patients.